政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/22337
English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  全文筆數/總筆數 : 114907/145944 (79%)
造訪人次 : 54016031      線上人數 : 926
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋


    請使用永久網址來引用或連結此文件: https://nccur.lib.nccu.edu.tw/handle/140.119/22337


    題名: Utilization of hepatoprotectants within the National Health Insurance in Taiwan
    作者: Chen,Tzeng-Ji;周麗芳;Hwang,Shinn-Jang
    關鍵詞: drug utilization;liver diseases;national health programs;pharmacoepidemiology;protective agents
    日期: 2003-07
    上傳時間: 2009-01-06 15:25:15 (UTC+8)
    摘要: Background: Although the hepatoprotectants of Western medicine have centuries of history, their utilization patterns have been seldom documented. Because the National Health Insurance program in Taiwan reimburses hepatoprotectant use, we could estimate the age- and sex-specific prevalence and utilization patterns of hepatoprotectants in Western medicine within the health insurance system in Taiwan. Methods: We analyzed the outpatient prescription data of 50 000 randomly sampled insured patients in 2000. Only patients using drugs indicated for liver diseases and diagnostic codes related to liver diseases on the same visit were considered to be receiving hepatoprotectants. Drugs involved in Chinese medicine were not included. Results: Among the valid cohort of 46 614 people, 783 (1.7%) were identified as patients with liver disease and receiving hepatoprotectants. Highest prevalence of hepatoprotectant use was 4.9% in the 60–69 years age group. Silymarin, multivitamins, methionine, ursodeoxycholic acid, and liver hydrolysate accounted for 88.8% of the 3215 prescribed items of hepatoprotectants. Patients receiving hepatoprotectants had, on average, visited the clinics more frequently than those not using hepatoprotectants (30 vs 14 times in a year, P < 0.001), and used more insurance benefits (US$1352 vs US$456, P < 0.001). Conclusions: The frequency of use of major hepatoprotectants in Taiwan corresponded to the current modalities of treatment under discussion worldwide. © 2003 Blackwell Publishing Asia Pty Ltd.
    關聯: Journal of Gastroenterology and Hepatology, 18(7), 868-872
    資料類型: article
    DOI 連結: http://dx.doi.org/10.1046/j.1440-1746.2003.03078.x
    DOI: 10.1046/j.1440-1746.2003.03078.x
    顯示於類別:[財政學系] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    j.1440-1746.pdf68KbAdobe PDF21304檢視/開啟


    在政大典藏中所有的資料項目都受到原著作權保護.


    社群 sharing

    著作權政策宣告 Copyright Announcement
    1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
    The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

    2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
    NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋